Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Cosmet Dermatol ; 21(1): 331-336, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33721390

RESUMEN

BACKGROUND: Keloid is a benign well-demarcated overgrowth of fibrotic tissue which extends beyond the original boundaries of a defect. The treatment of keloids is a particular challenge to dermatologists. Intralesional corticosteroid injection has been considered the first-line treatment for keloids. Vitamin D plays an important role in cell proliferation and differentiation as it slows the progression of tissue fibrosis by keloid fibroblasts and inhibits collagen synthesis in dermal fibrosis. OBJECTIVES: To evaluate the efficacy of intralesional injection of vitamin D in the treatment of keloids, both clinically and ultrasonically. METHODS: Forty Egyptian patients with keloid scars were injected weekly with intralesional vitamin D with dose of 0.2 ml (200,000 IU) per 1 cm lesion. The keloid scars were evaluated with Vancouver Scar Scale (VSS) and by a high-resolution ultrasound using B mode before and after treatment, the patients received 3 to 4 sessions. RESULTS: There was statistically highly significant reduction in VSS after treatment with intralesional vitamin D injection (p value≤0.001). There was also statistically highly significant improvement in ultrasonic keloid scar thickness after treatment (P value ≤0.001). CONCLUSIONS: Intralesional vitamin D is an effective and safe method in treatment of keloid scars. Ultrasound is a useful method in assessing the improvement of keloids after treatment.


Asunto(s)
Cicatriz Hipertrófica , Queloide , Corticoesteroides , Cicatriz Hipertrófica/tratamiento farmacológico , Humanos , Inyecciones Intralesiones , Queloide/tratamiento farmacológico , Queloide/patología , Resultado del Tratamiento , Vitamina D/uso terapéutico
2.
Dermatol Ther ; 33(6): e14333, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32975877

RESUMEN

Onychomycosis (OM) is a chronic fungal infection of the nail caused by dermatophytes, yeasts, and nondermatophytes. Tioconazole is one of the topical antifungal belonging to imidazole derivatives. Tazarotene is a synthetic retinoid, with immunomodulating properties and anti-inflammatory activity. To evaluate the efficacy of tazarotene 0.1% gel alone in comparison with its combination with tioconazole nail paint in the treatment of onychomycosis. Forty patients presented with onychomycosis, subjected to a full history taking, clinical examination, and nail examination, which includes a clinical, dermoscopic, assessment of severity by using Onychomycosis Severity Index (OSI), KOH examination, and fungal culture. There was a statistically significant increase in the response of treatment in patients treated by a combination of tazarotene and tioconazole compared to tazarotene alone through (decrease in OSI, dermoscopic features, and mycological clearance). Tazarotene had antifungal activity specially against Aspergillus niger while its combination with tioconazole gave better results and can be used as an adjuvant to the standard systemic or topical antifungal treatment for OM.


Asunto(s)
Onicomicosis , Administración Tópica , Antifúngicos/uso terapéutico , Humanos , Imidazoles/uso terapéutico , Ácidos Nicotínicos , Onicomicosis/diagnóstico , Onicomicosis/tratamiento farmacológico , Pintura
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA